Literature DB >> 17517846

High-affinity, human antibody-like antibody fragment (single-chain variable fragment) neutralizing the lethal factor (LF) of Bacillus anthracis by inhibiting protective antigen-LF complex formation.

Thibaut Pelat1, Michael Hust, Emmanuelle Laffly, Florence Condemine, Chantal Bottex, Dominique Vidal, Marie-Paule Lefranc, Stefan Dübel, Philippe Thullier.   

Abstract

The anthrax lethal toxin (LT) consists of two subunits, the protective antigen (PA) and the lethal factor (LF), and is essential for anthrax pathogenesis. Several recombinant antibodies directed against PA and intended for medical use have been obtained, but none against LF, despite the recommendations of anthrax experts. Here we describe an anti-LF single-chain variable fragment (scFv) that originated from an immunized macaque (Macaca fascicularis) and was obtained by phage display. Panning of the library of 1.8 x 10(8) clones allowed the isolation of 2LF, a high-affinity (equilibrium dissociation constant, 1.02 nM) scFv, which is highly neutralizing in the standardized in vitro assay (50% inhibitory concentration, 1.20 +/- 0.06 nM) and in an in vivo assay. The scFv neutralizes anthrax LT by inhibiting the formation of the LF-PA complex. The genes encoding 2LF are very similar to those of human immunoglobulin germ line genes, sharing substantial (84.2%) identity with their most similar, germinally encoded counterparts; this feature favors medical applications. These results, and others formerly published, demonstrate that our approach can generate antibody fragments suitable for prophylaxis and therapeutics.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17517846      PMCID: PMC1932538          DOI: 10.1128/AAC.01528-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  56 in total

1.  Knowledge-based design of reagentless fluorescent biosensors from recombinant antibodies.

Authors:  Martial Renard; Laurent Belkadi; Nicolas Hugo; Patrick England; Danièle Altschuh; Hugues Bedouelle
Journal:  J Mol Biol       Date:  2002-04-26       Impact factor: 5.469

2.  IMGT/V-QUEST, an integrated software program for immunoglobulin and T cell receptor V-J and V-D-J rearrangement analysis.

Authors:  Véronique Giudicelli; Denys Chaume; Marie-Paule Lefranc
Journal:  Nucleic Acids Res       Date:  2004-07-01       Impact factor: 16.971

3.  Evaluation and binding-mode prediction of thiopyrone-based inhibitors of anthrax lethal factor.

Authors:  Jana A Lewis; John Mongan; J Andrew McCammon; Seth M Cohen
Journal:  ChemMedChem       Date:  2006-07       Impact factor: 3.466

4.  Analysis of mass transport-limited binding kinetics in evanescent wave biosensors.

Authors:  P Schuck; A P Minton
Journal:  Anal Biochem       Date:  1996-09-05       Impact factor: 3.365

5.  Protection against anthrax lethal toxin challenge by genetic immunization with a plasmid encoding the lethal factor protein.

Authors:  B M Price; A L Liner; S Park; S H Leppla; A Mateczun; D R Galloway
Journal:  Infect Immun       Date:  2001-07       Impact factor: 3.441

6.  Characterization of lethal factor binding and cell receptor binding domains of protective antigen of Bacillus anthracis using monoclonal antibodies.

Authors:  Stephen F Little; Jeanne M Novak; John R Lowe; Stephen H Leppla; Yogendra Singh; Kurt R Klimpel; Burton C Lidgerding; Arthur M Friedlander
Journal:  Microbiology (Reading)       Date:  1996-03       Impact factor: 2.777

7.  Preclinical development of keliximab, a Primatized anti-CD4 monoclonal antibody, in human CD4 transgenic mice: characterization of the model and safety studies.

Authors:  P J Bugelski; D J Herzyk; S Rehm; A G Harmsen; E V Gore; D M Williams; B E Maleeff; A M Badger; A Truneh; S R O'Brien; R A Macia; P J Wier; D G Morgan; T K Hart
Journal:  Hum Exp Toxicol       Date:  2000-04       Impact factor: 2.903

8.  Anthrax lethal factor inhibition.

Authors:  W L Shoop; Y Xiong; J Wiltsie; A Woods; J Guo; J V Pivnichny; T Felcetto; B F Michael; A Bansal; R T Cummings; B R Cunningham; A M Friedlander; C M Douglas; S B Patel; D Wisniewski; G Scapin; S P Salowe; D M Zaller; K T Chapman; E M Scolnick; D M Schmatz; K Bartizal; M MacCoss; J D Hermes
Journal:  Proc Natl Acad Sci U S A       Date:  2005-05-23       Impact factor: 11.205

9.  Evaluation of safety and clinical activity of multiple doses of the anti-CD80 monoclonal antibody, galiximab, in patients with moderate to severe plaque psoriasis.

Authors:  Alice B Gottlieb; Sewon Kang; Kenneth G Linden; Mark Lebwohl; Alan Menter; Ahsan A Abdulghani; Michael Goldfarb; Nicole Chieffo; Mark C Totoritis
Journal:  Clin Immunol       Date:  2004-04       Impact factor: 3.969

10.  Human anti-anthrax protective antigen neutralizing monoclonal antibodies derived from donors vaccinated with anthrax vaccine adsorbed.

Authors:  Ritsuko Sawada-Hirai; Ivy Jiang; Fei Wang; Shu Man Sun; Rebecca Nedellec; Paul Ruther; Alejandro Alvarez; Diane Millis; Phillip R Morrow; Angray S Kang
Journal:  J Immune Based Ther Vaccines       Date:  2004-05-12
View more
  48 in total

1.  A comparison of human and macaque (Macaca mulatta) immunoglobulin germline V regions and its implications for antibody engineering.

Authors:  Philippe Thullier; Siham Chahboun; Thibaut Pelat
Journal:  MAbs       Date:  2010-09-01       Impact factor: 5.857

Review 2.  Discovery of protective B-cell epitopes for development of antimicrobial vaccines and antibody therapeutics.

Authors:  Jacqueline Sharon; Michael J Rynkiewicz; Zhaohua Lu; Chiou-Ying Yang
Journal:  Immunology       Date:  2014-05       Impact factor: 7.397

3.  Non-human primate immune libraries combined with germline humanization: an (almost) new, and powerful approach for the isolation of therapeutic antibodies.

Authors:  Thibaut Pelat; Philippe Thullier
Journal:  MAbs       Date:  2009-07-05       Impact factor: 5.857

4.  Cathelicidin administration protects mice from Bacillus anthracis spore challenge.

Authors:  Mark W Lisanby; Melissa K Swiecki; Brian L P Dizon; Kathryn J Pflughoeft; Theresa M Koehler; John F Kearney
Journal:  J Immunol       Date:  2008-10-01       Impact factor: 5.422

5.  Sequential B-cell epitopes of Bacillus anthracis lethal factor bind lethal toxin-neutralizing antibodies.

Authors:  Melissa L Nguyen; Sherry R Crowe; Sridevi Kurella; Simon Teryzan; Brian Cao; Jimmy D Ballard; Judith A James; A Darise Farris
Journal:  Infect Immun       Date:  2008-11-03       Impact factor: 3.441

6.  Enhancement of antibody responses to Bacillus anthracis protective antigen domain IV by use of calreticulin as a chimeric molecular adjuvant.

Authors:  Yong Sung Park; Jin Hyup Lee; Chien-Fu Hung; T-C Wu; Tae Woo Kim
Journal:  Infect Immun       Date:  2008-02-19       Impact factor: 3.441

7.  Isolation of a human-like antibody fragment (scFv) that neutralizes ricin biological activity.

Authors:  Thibaut Pelat; Michael Hust; Martha Hale; Marie-Paule Lefranc; Stefan Dübel; Philippe Thullier
Journal:  BMC Biotechnol       Date:  2009-06-30       Impact factor: 2.563

8.  Identification of a putative Crf splice variant and generation of recombinant antibodies for the specific detection of Aspergillus fumigatus.

Authors:  Mark Schütte; Philippe Thullier; Thibaut Pelat; Xenia Wezler; Philip Rosenstock; Dominik Hinz; Martina Inga Kirsch; Mike Hasenberg; Ronald Frank; Thomas Schirrmann; Matthias Gunzer; Michael Hust; Stefan Dübel
Journal:  PLoS One       Date:  2009-08-13       Impact factor: 3.240

9.  IMGT/3Dstructure-DB and IMGT/DomainGapAlign: a database and a tool for immunoglobulins or antibodies, T cell receptors, MHC, IgSF and MhcSF.

Authors:  François Ehrenmann; Quentin Kaas; Marie-Paule Lefranc
Journal:  Nucleic Acids Res       Date:  2009-11-09       Impact factor: 16.971

10.  Isolation and chimerization of a highly neutralizing antibody conferring passive protection against lethal Bacillus anthracis infection.

Authors:  Ronit Rosenfeld; Hadar Marcus; Einat Ben-Arie; Bat-El Lachmi; Adva Mechaly; Shaul Reuveny; Orit Gat; Ohad Mazor; Arie Ordentlich
Journal:  PLoS One       Date:  2009-07-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.